Lung Cancer

P3, N=200, Recruiting, NRG Oncology | Trial primary completion date: Jul 2028 --> Jun 2026

P2, N=13, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=27 --> 13

Through a comprehensive and systematic search of the best available evidence, the Neoplastic Diseases Task Force developed 20 recommendations on screening and risk factor assessment for 10 specific questions on neoplastic diseases. These recommendations serve as guidance on screening neoplastic diseases at the primary care level.

Adjuvant targeted therapy did not improve long-term survival in stage IB EGFR-mutant NSCLC with high-risk features, although it prolonged DFS in pure-solid tumors. A de-escalation strategy may be considered for postoperative management, particularly in part-solid tumors.

In addition, SGO2 compromised the cisplatin (CDDP) sensitivity of LUAD in vitro and in vivo...Silencing SGO2 with OA improved LUAD chemo sensitivity. Our work highlights the potential of SGO2 as a target for therapeutic intervention and OA as a food-bioactive compound for LUAD treatment.

Despite pembrolizumab discontinuation, both patients maintained durable systemic disease control. These cases emphasize the importance of recognizing uncommon radiological patterns such as the atoll sign in patients receiving ICIs, highlighting the need for vigilance even after prolonged therapy and underscoring the potential for sustained oncologic benefit despite treatment discontinuation.

This "split-loading, activation-after-entry" strategy decouples probe delivery from activation, minimizing background leakage, while the rigid nanoball architecture provides robust nuclease protection. Using lung cancer cells as a model, we demonstrate that DNB-3DCHA enables high-contrast, spatiotemporally controlled in situ imaging of miR-155 with excellent specificity and signal-to-noise ratio, offering a promising tool for cancer diagnostics.

Pan-TRK IHC has a false-positive rate of ∼4%, particularly in squamous cell carcinomas, underscoring the need for confirmatory NGS to validate IHC findings and assess fusion functionality. Functional NTRK1/2/3 fusions remain exceedingly rare in NSCLC, with a detection rate of 0.03% across our combined cohorts.

Data suggest that drugs used in the treatment of MS can modify ACE2 expression; specifically, fingolimod reduces ACE2 expression and may have a protective role against SARS-CoV-2 infection.

Subtyping based on single-cell derived marker genes and multi-level analyses provide a comprehensive understanding of LUAD biology. The distinct features of C1 and C2 subtypes highlight the need for tailored therapies. The eight-gene signature may serve as a novel prognostic, diagnostic, and therapeutic indicator.

Platinum/PEM/Pembro may be a therapeutic option for TTF-1-negative non-sq NSCLC with good PS and adenocarcinoma histology, although careful management of irAE is required.

NFIC/METTL3 negative feedback loop in NSCLC cells suppresses exosomal miR-194-5p via m6A methylation; reduced miR-194-5p deepresses ZNF106 in macrophages, promoting M2 polarization and IL-6 secretion; Macrophage-derived IL-6 activates JAK2/STAT3 in NSCLC cells to upregulate METTL3, forming a positive feedback loop.